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reach threshold before age 40. The threshold is 1 to 2
years lower if 50% rather than 20% of new angina is
considered to be incapacitating. CONCLUSION: The
methodology provides a precise, accurate method for es-
timation of CVD risk for commercial and private pilots.
The new method introduces objectivity and a level ‘play-
ing field’ for assessment of pilot cardiovascular risk.
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Inhaled steroid agents are recommended for patients with
chronic asthma. OBJECTIVE: The objective of this study
was to compare asthma-related prescription and medical
costs between a cohort of patients with inhaled steroid
use (experimental) and without inhaled steroid use (con-
trol). METHODS: 99 Medicaid patients with an asthma
diagnosis who received add-in inhaled steroids were
matched to 99 patients with an asthma diagnosis who
used therapies other than inhaled steroids. Data were col-
lected for the 6 months before the addition of an inhaled
steroid (pre-utilization phase); for the 6 months immedi-
ately after the addition (stabilization phase); and for the
6 months after the stabilization phase (post-utilization
phase). RESULTS: Compared to the pre-utilization phase,
prescription costs in the post-utilization phase increased
by an average of $57 per month for the experimental
group, while only increasing by an average of $4 per
month for the control group. Conversely, compared to
the pre-utilization phase, medical costs in the post-utili-
zation phase decreased by an average of $53 per month
for the experimental group and increased by an average
of $14 per month for the control group. These cost data
were not normally distributed. Statistical comparisons
using various methods addressing skewed data were con-
sidered (Mann-Whitney U, log transformation, and boot-
strapping). The advantages and disadvantages of using
each method will be outlined. CONCLUSION: The data
indicate that the addition of inhaled steroids increases
prescription costs while decreasing medical costs. The
level of statistical significance differs depending on the
type of test used.
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BACKGROUND: During a retrospective study of intra-
abdominal infections we found that case notes for adult
patients were destroyed or incompletely microfiched if
the patient had no contact with the hospital for six years.
OBJECTIVES: To test the hypothesis that patients with
unobtainable case notes would have higher in-hospital
mortality and that this would bias the study sample.
METHODS: Patients who might have community ac-
quired intra-abdominal infections were identified at three
acute hospitals from Scottish Morbidity Records (SMR)
for 1993 to 1995 by the following ICD9 codes: 567
(peritonitis); 540 (appendicitis); 531–534 (gastric, duode-
nal, peptic or gastrojejunal ulcers with perforation).
Medical records were obtained to validate the diagnosis
and to obtain details of antibiotic therapy and its out-
come. If medical records were unobtainable the date of
death and duration of admission were identified from the
electronic SMR record. RESULTS: A total of 867 cases
were identified. For 339 (39%) of these, case notes were
unobtainable or incomplete. SMR could be used to calcu-
late in hospital mortality and duration of stay for 334
(98%) of patients with unobtainable or incomplete medi-
cal records and 510 (97%) of patients with complete
notes. The proportion of female patients was similar
(51% versus 50%). However, the patients with unob-
tainable or incomplete records were significantly older
(median age 72 versus 53.5; P  0.0001 Wilcoxon test)
and significantly more of them died in hospital (45% ver-
sus 7%; relative risk of death in hospital 6.75; 95% CI
5.08–8.96). Median length of stay (10 days versus 9
days; P  0.27 Wilcoxon test) and total hospital cost
(£2885 versus £2746; P  0.68) were similar in the two
groups. CONCLUSION: Missing data have biased the
study sample by excluding older patients with worse out-
come. Selective destruction of case notes is an important
source of bias in retrospective outcomes studies.
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OBJECTIVE: To review the baseline similarities and dif-
ferences between olanzapine- and risperidone-treated pa-
tients, as described in epidemiologic studies, and recom-
mend a set of potential confounders that should be
addressed in such studies. METHOD: All 24 non-ran-
domized olanzapine-risperidone comparisons cited in
Medline or presented as posters at major psychiatric con-
ferences (APA, ECNP, WPA) through 1999 were in-
cluded. The direction, magnitude, and statistical signifi-
cance of all baseline comparisons of the two treatment
groups were recorded, if available. RESULTS: Across all
use, diagnosis distribution and mean age differed without
consistent direction. Comorbidities, number of different
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prior antipsychotics, and prior use of second line treat-
ments were greater for olanzapine users, while percent
with any prior antipsychotic use was not significantly
different. Within schizophrenia, olanzapine users were
more likely to be male, have earlier age of onset, and lower
mean age. Most schizophrenia-specific studies included
no baseline service utilization or clinical measures; how-
ever, one study showed higher previous hospital costs for
olanzapine-treated patients. CONCLUSIONS: Mean age,
gender, diagnosis, age at onset, history of antipsychotic
use and prior costs differed for olanzapine- and risperi-
done-treated patients, with olanzapine-treated patients
having a history indicative of higher cost and treatment-
failure. Non-randomized studies must address these fac-
tors to avoid misleading interpretations of their results.
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The development of evidence-based practice guidelines
should be informed by the best evidence regarding the
quality and efficiency of care. Rigorous economic and
cost-effectiveness analyses provide relevant information
about the efficiency of care. OBJECTIVE: We sought to
determine the extent to which economic analyses are con-
sidered in the guideline development process. METHODS:
Using acute myocardial infarction as a sample condition,
we performed a systematic review of the published litera-
ture from 1996–1999 for national/international guide-
lines (e.g. AHA, ACC, ACP) and from 1990–1998 for
economic analyses. Economic analyses were first assessed
for methodologic quality using a structured scoring sys-
tem with high quality analyses scoring 70% or above. In-
clusion criteria were economic analyses that 1) predated
guideline publication by one or more years, and 2) as-
sessed interventions relevant to the guideline topics. A
matrix was constructed to determine the potential inclu-
sion of economic analyses in guidelines according to
these criteria. Two independent reviewers evaluated the
text and references of each guideline to quantify actual
inclusion. RESULTS: Six guidelines and 30 economic
analyses (17 high quality) were identified. Although the
30 analyses merited inclusion across the 6 guidelines in
94 instances, text mention occurred only 4% (4/94) of
the time and referencing occurred only 10% (9/94) of the
time. Similarly, the 17 high quality analyses merited in-
clusion in 61 instances but text mentions and referencing
were 3% (2/61) and 7% (4/61), respectively. Fifty per-
cent (3/6) of the guidelines mentioned at least one eco-
nomic analysis in the text and 67% (4/6) referenced at
least one; results for high quality analyses were 17% (1/6)
and 50% (3/6), respectively. CONCLUSION: Rigorous
economic analyses are infrequently considered in the de-
velopment of prestigious national guidelines. A system-
atic approach should be developed to ensure the compre-
hensive consideration of all relevant economic analyses in
the guideline development process.
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AD is a progressive disease with a large impact on health
care resources and health-related quality of life. How-
ever, in many clinical trials, health state utilities have not
been measured. OBJECTIVES: To determine a method
of deriving utility changes from efficacy outcome scales
in AD suitable for cost-effectiveness analysis. METH-
ODS: As an example of cognitive enhancer therapy, data
from the metrifonate in AD Trial (MALT), involving 393
patients, was used for outcome data. Utilities were esti-
mated by using selected subscales and mapping them to
equivalent Health Utilities Index Mark III (HUI:3) items.
The domains of ‘emotion’, ‘cognition’ and ‘self-care’
were mapped from their respective equivalent on the
Neuropsychiatric Inventory Scale and Global Deteriora-
tion Scale. Other HUI:3 domains were non-contributory
and were scored as 1’. Changes in utility from baseline to
6 months post-treatment were quantified using each
HUI:3 mapped subscale score. RESULTS: Drug im-
proved cognition, emotion and independence, and re-
duced behavioral disorders. The calculated utilities dis-
criminated between drug and placebo at 6 months (mean
utility change  0.028 and 0.023, respectively, P 
0.01). Also, it discriminated between AD stages (mild mi-
nus moderate  0.056) and between presence and ab-
sence of behavioural disorders (difference  0.16 [mild
AD] and 0.18 [moderate AD]). The significant changes in
cognition and behaviors therefore translated into a mod-
erate gain in utility (0.051) with drug over 6 months.
CONCLUSIONS: Mapping treatment outcome scales to
HUI:3 can be used successfully to derive a measure of
health utility change. This method may be implemented
in cost-effectiveness analysis. Currently, metrifonate is
under active review by regulatory bodies.
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